SUPPLEMENTARY MATERIAL

List of investigators

Belgium

Daniel Blockmans Leuven Frédéric Vandergheynst Brussels

Canada

Frederic Morin Quebec

Denmark

Jesper Noerregaard Hillerod

France

Valerie Devauchelle Pensec Brest
Eric Hachulla Lille
Gilles Kaplanski Marseille
Pierre Kieffer Mulhouse
Claire Larroche Bobigny
Alexis Regent Paris

Germany

Rieke H.-E. Alten Berlin

Martin Aringer Dresden

Juergen Braun Herne

Martin Fleck Bad Abbach

Bernhard Hellmich Plochingen

Joerg Christoph Henes Tübingen

Jan Leipe Munich

Frank Moosig Bad Bramstedt

Thomas Neumann Jena
Juergen Rech Erlangen
Reinhold Ernst Schmidt Hannover
Andreas Schwarting Mainz
Reinhard Voll Freiburg

Italy

Silvano Adami Verona
Stefano Bombardieri Pisa
Marco Amedeo Cimmino Genova
Salvatore de Vita Udine
Amelia Ruffatti Padova
Maria Grazia Sabbadini Milano

Carlo Salvarani Reggio Emilia

Netherlands

Amanda J. W. Branten Arnhem Elisabeth Brouwer Groningen

Edgar M. Colin Almelo M. Vonk Nijmegen Alexandre Voskuyl Amsterdam

Norway

Maud-Kristine Ljoså Ålesund Geirmund Myklebust Kristiansand Øyvind Palm Oslo

Poland

Marek Brzosko Szczecin Slawomir Jeka Bydgoszcz

Portugal

António Marinho Porto

Spain

Eduardo Ucar Angulo Bilbao Maria C. Cid Barcelona Francisco Javier Blanco Garcia A Coruna Francisco Javier Narvaez Garcia Barcelona Federico Diaz Gonzalez La Laguna

Sweden

Peter Matt Uppsala Alladin Mohammad Lund Elisabeth Nordborg Goteborg Elke Theander Malmö Ronald van Vollenhoven Stockholm

United Kingdom

Adewale Adebajo Barnsley Neil Basu Aberdeen Paul Byrne Colchester

Bhaskar Dasgupta Westcliffe-on-Sea

David Hutchinson Truro Neil McKay Edinburgh Birmingham Susan Mollan Ann Morgan Leeds

Pamela Peterson Newcastle upon Tyne

Gordon Plant London Euthalia Roussou Romford

United States of America

Vera Bocoun Wausau Lindsy Forbess Los Angeles Joseph Z. Forstot **Boca Raton** Daniel E Furst Los Angeles William Gough Asheville Jeffrey Kaine Sarasota

Brian Keroack Curry Koening Eric Matteson Peter Merkel Christopher Phillips Robert Spiera John H. Stone Andrew Sulich Sebastian Unizony Portland Salt Lake City Rochester Philadelphia Paducah New York Boston

St. Claire Shores

Boston

Box 1 Parameters tested as predictors of treatment failure

1. Patient-related features

Age

Sex

Race

Body mass index

2. Disease-related features

At the time of GCA diagnosis

Headaches

Scalp tenderness

Jaw claudication

GCA-related vision loss

Polymyalgia rheumatica symptoms

Temporal artery biopsy positive

Imaging demonstrating lesions compatible with large vessel vasculitis^a

At study baseline

New-onset disease

Disease duration

Erythrocyte sedimentation rate

C-reactive protein level

3. Treatment-related features

Baseline prednisone dose

4. Patient-reported outcomes

Patient Global Assessment of Disease Activity

Functional Assessment of Chronic Illness Therapy-Fatigue score

36-Item Short Form Survey physical component summary

36-Item Short Form Survey mental component summary

EuroQol-5D score

^aImaging included computed tomography angiography, magnetic resonance angiography, and

positron emission tomography

Table 1 GiACTA study definitions of patient-reported outcomes

Instrument	Description	
Patient Global	The PtGA score reflects patients' perceptions of their disease	
Assessment of Disease	activity, which is marked on a numerical scale (0-100 mm).	
Activity (PtGA)	Higher numbers indicate perception that disease activity is	
	worse.	
	Wolse.	
E		
Functional Assessment of	The FACIT-Fatigue scale is a 13-item tool that measures a	
Chronic Illness Therapy	patient's level of fatigue during their usual daily activities in	
(FACIT)-Fatigue scale	the past week. ² Fatigue and its impact on physical activity,	
	functionality and social interactions are measured on a four-	
	point Likert scale. The FACIT-Fatigue scale ranges from 0 to	
	52. Lower numbers indicate worse fatigue and greater impact	
	of fatigue on physical, functional and social outcomes.	
36-Item Short Form	The SF-36 is a 36-item, patient-reported survey of functional	
Survey (SF-36)	health and well-being that captures data related to eight	
	health domains (physical functioning, bodily pain, role	
	limitations due to physical health problems, role limitations	
	due to emotional problems, emotional well-being, social	
	functioning, energy/fatigue and perception of general	
	health). ³ The SF-36 scores range from 0 to 100. Lower scores	
	indicate less favourable health states.	

EuroQol-5D (EQ-5D)	The EQ-5D is a standardised instrument for measuring	
score	generic health status that gathers data regarding patient	
	mobility, self-care, pain, depression/anxiety and usual	
	activities (e.g. work, study, housework and family or leisure	
	activities). ⁴ The EQ-5D score ranges from 0 to 1. Lower	
	numbers indicate worse health status.	

Table 2 Causes of nonresponse to treatment

Cause, n (%)	PBO/PDN	TCZ/PDN
Cause, II (70)	N=101	N=149
Treatment failure	67 (66.3)	44 (29.5)
Refractory disease	31 (30.7)	18 (12.1)
Disease relapse	36 (35.6) [†]	26 (17.4) [‡]
Other	7 (6.9)	19 (12.8)
Treatment discontinuation because of an adverse	3 (3.0)	8 (5.4)
event		
Nonadherence to the protocol prednisone taper	1 (1)	4 (2.7)
Study withdrawal before week 52	2 (5.2)	4 (2.7)
Miscellaneous*	1 (1)	3 (2.0)

^{*}Miscellaneous reasons included protocol violation and protocol noncompliance.

PBO/PDN, placebo + prednisone; TCZ/PDN, tocilizumab + prednisone.

[†]Relapse in eight patients was based on isolated elevation of erythrocyte sedimentation rate.

[‡]Relapse in one patient was based on isolated elevation of erythrocyte sedimentation rate.

REFERENCES

- Nikiphorou E, Radner H, Chatzidionysiou K, et al. Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther 2016;18:251.
- Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. *J Pain Symptom Manage* 1997;13:63-74.
- Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. *Med Care* 1992;30:473-83.
- 4 EuroQol G. EuroQol—a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16:199-208.